BPC-157 with KPV: no study has combined them, both have only animal colitis work, what the FDA says of each, the KLOW blend's molar split, and units.
BPC-157 with KPV is searched as a gut-focused pairing: a fifteen-amino-acid fragment from a gastric protein next to the last three amino acids of alpha-MSH. The appeal is easy to state. Both are sold for inflammation, both have colitis studies, and both are cheap to add. What the record holds is narrower: separate animal studies for each peptide, no study of the two together, and an FDA statement that it has found no human exposure data for KPV at all.
The single-compound records are on the BPC-157 dosage page and the KPV dosage page. The four-peptide blend that contains both is compared with its three-peptide sibling on GLOW vs KLOW, and BPC-157's better-known pairing is on BPC-157 vs TB-500.
The registry, counted
ClinicalTrials.gov returned zero studies for KPV on 2026-10-10. For BPC-157 it returned four, none of which involves KPV and none of which states an injected dose: two sponsor registrations posted in 2026, a planned university trial and a 2015 oral tablet study. PubMed returned one record naming both peptides, a 2026 review of the FDA compounding committee's recommendations on synthetic peptides, written for pharmacists. It describes the committee's concerns; it gives neither peptide to anyone.
What each record holds
|
BPC-157 |
KPV |
| What it is |
15-amino-acid fragment of a gastric protein (GEPPPGKPADDAGLV) |
Lys-Pro-Val, the last three residues of alpha-MSH |
|---|
| Molecular weight |
1,419.5 (PubChem CID 9941957) |
342.43 (PubChem CID 125672) |
|---|
| Approved product |
None |
None |
|---|
| Registered human trials |
Four records, none with a stated injected dose |
None |
|---|
| Gut evidence |
Rat colitis and anastomosis models |
Two mouse colitis models (2008) |
|---|
| FDA bulk-substance page |
Immunogenicity, impurity and characterisation concerns |
"Has not identified any human exposure data" by any route |
|---|
Two colitis literatures that never meet
KPV's case rests on two mouse papers from 2008. Kannengiesser and colleagues gave it in two colitis models and reported earlier recovery, regained weight and fewer inflammatory cells; in mice with a non-working melanocortin-1 receptor every treated animal survived the colitis, so in that model the effect did not need that receptor. Dalmasso and colleagues showed the tripeptide entering gut cells through the transporter PepT1, which is why so much later KPV work is about oral delivery systems.
BPC-157's gut work is in rats, mostly from one group in Zagreb. Their 2012 review of ulcerative colitis describes a peptide "stable in human gastric juice" and cites a phase II programme in inflammatory bowel disease under the code PL 14736. A full paper reporting that trial's results was not found for this page. So the human gut evidence for either peptide is, at most, a trial reported by its developers in a review.
The two literatures use different species, different models and different measures, and no paper puts the peptides in the same animal. The idea that they add up is reasoning from two separate rodent results, not a finding.
The molecule count most pages skip
Stack pages compare the two in milligrams, which hides how unequal the doses are as molecules. KPV is a quarter of BPC-157's size.
| Amount |
BPC-157 |
KPV |
| 250 mcg |
0.18 µmol |
0.73 µmol |
| 500 mcg |
0.35 µmol |
1.46 µmol |
| 10 mg (one KLOW share) |
7.0 µmol |
29.2 µmol |
In a KLOW vial, equal milligrams of the two mean about four KPV molecules for every BPC-157 molecule. Whether that matters is unknown, because neither peptide has a human dose-response curve; the table shows only what an equal-mass label hides.
| Figure |
Source |
Note |
| BPC-157 250–500 mcg, once or twice daily |
Vendor, clinic and forum pages |
No trial behind it |
| KPV 200–500 mcg injected, once or twice daily |
Vendor pages |
No trial behind it |
| KPV 250 mcg–1 mg by mouth |
Vendor pages |
Cannot be converted to syringe units |
| BPC-157 10 mcg/kg in rats |
64 indexed abstracts |
800 mcg at 80 kg by body weight; not a human dose |
| KPV 100 µM in drinking water, mice |
Dalmasso 2008 |
No milligram dose tested |
The vendor figures were read on this site's single-compound pages on 2026-09-18 and are reported as what circulates. No source ties any of them to the combination.
Reconstitution and the units per draw
Units on a U-100 syringe = mg ÷ mg/mL × 100.
| Amount |
2.5 mg/mL |
5 mg/mL |
| 200 mcg |
8 units |
4 units |
| 250 mcg |
10 units |
5 units |
| 500 mcg |
20 units |
10 units |
2.5 mg/mL is a 5 mg vial with 2 mL or a 10 mg vial with 4 mL; 5 mg/mL is a 10 mg vial with 2 mL. With two separate vials, each amount is drawn from its own vial and the two can differ. In a blend vial they cannot: in KLOW at its listed split, every unit drawn holds BPC-157 and KPV in equal milligrams, plus five times as much GHK-Cu. Every water volume for the 80 mg vial is worked per peptide on KLOW reconstitution; the blend calculator works a blend's per-draw amounts, and the BPC-157 vial arithmetic and KPV calculator setting work single vials.
No study has given BPC-157 and KPV together, neither has a published human dose, and the FDA states it has found no human exposure data for KPV. The gut evidence for both is in rodents. Nothing on this page is a dose, a schedule or a plan. The compounds are covered in Medibact's BPC-157 guide and KPV guide; product and dose belong with a prescriber.
Sources and dates
Opened 2026-10-10: ClinicalTrials.gov searches for KPV (0) and BPC-157 (4 records); the PubMed search for BPC-157 with KPV (1 record, PMID 42752426, abstract read); the abstracts of Kannengiesser et al. 2008 (PMID 18092346) and Sikiric et al. 2012 (PMID 22300085); the PubChem records for Lys-Pro-Val (CID 125672) and BPC-157 (CID 9941957); FDA's page on bulk drug substances that may present significant safety risks (content current as of 2026-04-22). Carried from this site's pages with their read dates: Dalmasso et al. 2008 and the KPV vendor figures (KPV page, 2026-09-18), BPC-157's registry, rat regimen and vendor figures (BPC-157 page, 2026-09-18), and the KLOW listing split (GLOW vs KLOW page, 2026-09-23). Molecule counts and units are arithmetic by this site. Corrections go to the contact page.
